Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-myeloablative haploidentical HSCT with post-transplant cyclophosphamide for refractory hematological malignancies
jRCTs051180119Recruiting
- Start
- Dec 2017
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fludarabine, busulfan and cyclophosphamide in hematopoietic malignancies. Primary endpoint: Engraftment. Started Dec 2017; status: recruiting.
02
Drugs
fludarabinebusulfancyclophosphamide
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs051180119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180119.